Experts from the National Medical Research Center for Tuberculosis, Lung and Infectious Diseases of the Russian Ministry of Health have completed pre-clinical trials of a new inhaled drug.
Hot Topics
"The Lady with the Braids"Physics Unravels the Mystery of an "Unknown" Egyptian Mummy
CIFTIS 2026 promotes high-quality services trade
What does "Silent Hill: Town Fall" have in store?
This drug is based on a natural bacteriophage—a virus that kills the tuberculosis bacterium. Trials have shown its effectiveness against 50 different strains of Mycobacterium tuberculosis (Koch's bacillus), half of which are antibiotic-resistant. The treatment period is only two weeks. Researchers have collected comprehensive pharmacokinetic data and confirmed the absence of any toxic effects. Preparations are currently underway for the first phase of clinical trials in humans.
Vadim Avdeev, a researcher at the National Medical Research Center, says: "This is a completely effective drug for treating tuberculosis, with a mechanism of action different from antibiotics. In preclinical trials, it has shown high efficacy without the need to use it with traditional drugs. The animals inhaled the drug (D29), and we compared the results with a standard combination of isoniazid and rifampicin, and it showed superior results. The standard duration of antibiotic treatment ranges from six to twelve months. We plan to use the drug for only two weeks."
In the first phase of clinical trials, doctors will test the drug's safety on healthy volunteers. The second phase will focus on its effectiveness, which will be evaluated in patients. The drug will be tested both alone and in combination with other medications.
what is your opinion on this news ?do let us know in the comments on tha comment box
if you liked this news article please share on friends & family & don't forget to follow on website & social media